MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:29Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Anticoagulants]]
			[[Category:Direct factor Xa inhibitors]]
			[[Category:DOACs]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #28

2026-05-23T03:34:49Z

parser-claude batch MedTemplate pre-fill, Top 300 #28

New page

{{MedTemplate
| generic = Apixaban
| brand = Eliquis
| structure =
| classes = [[:Category:Anticoagulants|Anticoagulant]], [[:Category:Direct_factor_Xa_inhibitors|Direct factor Xa inhibitor]], [[:Category:DOACs|Direct oral anticoagulant (DOAC)]]
| uses = <vote slug="nvaf-stroke-prevention-use">Stroke prevention in nonvalvular atrial fibrillation</vote>, <vote slug="vte-treatment-use">VTE treatment</vote>, <vote slug="vte-prophylaxis-use">VTE prophylaxis after hip/knee replacement</vote>
| starting_dose = NVAF: 5 mg PO BID (2.5 mg BID if 2 of 3: age ≥80, weight ≤60 kg, serum creatinine ≥1.5 mg/dL); acute VTE: 10 mg BID for 7 days, then 5 mg BID
| preparations = 2.5 mg, 5 mg tablets
| fda_max = 10 mg BID for the first 7 days of acute VTE; otherwise 5 mg BID
| pill_id =
| routes = Oral
| onset = Peak anticoagulant effect 3-4 hours
| duration = 12 hours
| halflife = ~12 hours<ref name="eliquis-label">FDA Prescribing Information, Eliquis (apixaban), Bristol-Myers Squibb, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202155s029lbl.pdf</ref>
| bioavailability = ~50% (oral; not significantly affected by food)<ref name="eliquis-label" />
| pregnancy = Avoid in pregnancy; switch to LMWH. Crosses placenta; data are limited but warfarin-class concerns about fetal hemorrhage and possible teratogenicity make heparins the preferred class.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="apixaban-mech-claim">Apixaban is a selective reversible direct inhibitor of activated factor X (Xa); blocking Xa interrupts thrombin generation at a stoichiometrically efficient point in the coagulation cascade, producing predictable anticoagulation without routine monitoring.</vote> CYP3A4 (primary) and P-glycoprotein substrate; strong dual inhibitors or inducers materially shift exposure. Reversal: andexanet alfa for life-threatening bleeding; 4F-PCC commonly used off-label when andexanet unavailable<ref name="eliquis-label" />.
}}

== References ==
<references />

Apixaban - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #28